Back to News
Market Impact: 0.15
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
Source: GlobeNewswire
Healthcare & Biotech
A milestone advances a Phase 3 program toward topline results expected in mid-2027. The article provides no further details about the program, milestone, or company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Why is NeoGenomics stock sliding today?
- Up 57% since June: this AI-picked pharma stock keeps climbing
- These stocks could benefit from a midterm election shake-up, JPMorgan says
- Vaxcyte shares surge on late-stage vaccine trial success